TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Capsular thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-procedure pain score using the Chronic Pain Behavioral Scale for Adults
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-procedure pain score using the standard 11-point numerical rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NK cells activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acquisition of cognitive skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Long-term tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Total to HDL Cholesterol Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in PCr/ATP ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HI antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutralization antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Remineralization of non-cavitated enamel lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Change From Baseline in PANSS Negative Symptoms Factor Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dependence according to DSM IV criteria
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increased uterine vascular flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in LCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in QTcF interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in ECG readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Sustained Improvement on Clinical Recovery Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Numerical Rating Scale (NRS) Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Large for Gestational Age (LGA) Infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Identification of Methicillin Resistant Staphylococcus aureus
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Pathologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return of bowel sound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fugl-Meyer Assessment (FMA-UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Modified Barthel ADL index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Major complications of gastric conduit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fibroblast growth factor 21 (FGF21)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days to Reach Full Enteral Feedings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Docosahexaenoic Acid (DHA) Levels in Whole Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number and size of the lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of drinks in past month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of drinks on a typical week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of peak drinks consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose of JNJ-54175446 in Part 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma and Cerebrospinal Fluid (CSF) Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of specific gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Numerical visual scale score for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of Crohns disease activity index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopy: improvement in appearance of lesions, or healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anatomopathology: improvement of histological criteria, or total regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline IPSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Qmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in strength of the fronto-parietal resting state network (RSN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number increase of Renal nerves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area increase of Renal nerves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Increase of the ratio of nerve area/artery wall area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean change in pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Event Combined Outcome: new ischemic stroke, acute coronary syndrome, or all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: NIBP Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number and proportion of voids associated with urgency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number and proportion of voids associated with Detrusor Overactivity episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time from PSG awakening to each void in minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Paresthesia coverage from stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change rate of restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximum tolerated dose (MTD) of inotuzumab ozogamicin (InO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lifestyle changes
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change of clinical symptoms by PANSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive improvement assessed using the MATRICS Consensus Cognitive Battery (MCCB) composite score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Variation of aneurysmal metrics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Number of T1 Gadolinium-Enhancing Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AUDIT Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ADS Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of toenails attaining Complete Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resistive index RI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diameter of the efferent vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Wall thickness of the efferent vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: 1st attempt success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Montgomery Asberg Depression Rating Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Functional Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in fetal stress hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incidence of grade ≥ 2 stomatitis
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of non-infectious pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Failure of defibrillation therapy (DT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Capillary diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activity evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Specific diagnosis of the patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin-to-skin interruptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the number of sweat glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the International Knee Documentation Committee (IKDC) score as a measure of Return to normal activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Tegner-Lysholm score as a measure of better function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in the Number (%) of Dystrophin Positive Fibers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of participants with acute and late morbidity of the eye
Endpoint domain: Adverse events/effects
Primary endpoint: Visual acuity per comprehensive eye exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Head Thrust Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Managed With Blood Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients with active serum Asparaginase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of Myocardial Perfusion Defect Excluding Significant CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hyaline cartilage production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of primary postpartum hemorrhage (PPH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: incidence of vasovagal episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Immune transcriptome profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sperm mRNAs expression profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of Participants With Adjudicated Symptoms of Hypersensitivity
Endpoint domain: Adverse events/effects
Primary endpoint: Time From Randomization to Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Free From Disease Progression or Death at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Fear and acrophobia levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Relative Change in Baseline Serum Alkaline Phosphatase (AP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician Erythema Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient Erythema Self Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in arterial inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in IART burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle strength in the quadriceps muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Monocytosis in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Hospitalizations Due to Respiratory Syncytial Virus (RSV)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of patients who complete pre-op treatment and proceed to surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain perception in second eye surgery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sequelae at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance Behavioural Avoidance Test (BAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adrenergic tone of the heart muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in DMN connectivity on rs-fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in DMN connectivity on TMS-EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Oxygen saturation value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of allogenic transfusion requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite of major bleeding and thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in MindStreams-NeuroTrax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Absence of ocular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of sympathetic ophthalmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmation of intraocular islet graft survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: phase II recommended dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CBR-24week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of subjects with dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: number of subjects with AEs
Endpoint domain: Adverse events/effects
Primary endpoint: clinical efficacy of MPH966
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of MPH966
Endpoint domain: Adverse events/effects
Primary endpoint: Enrollment in clinical trial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Stages of change
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Frequency of blood pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in antihypertensive medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of episodes of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient enrollment and adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: live birth rate per transferred cycle
Endpoint domain: Mortality/survival
Primary endpoint: Changes in total scores from baseline using Body Functionality Checklist
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: N-13 measured MBF value range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of topical medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decrease in Tricuspid Regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Other symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microscopic changes in esophageal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Delinquency
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Consumption of CF
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Signal to Noise Quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical infection with HPV-16 and/or HPV-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety and tolerability of Tecarfarin
Endpoint domain: Adverse events/effects
Primary endpoint: Change in xerostomia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in oral health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical VPS Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Convulsive Seizures Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stroke or Systemic Embolism
Endpoint domain: Mortality/survival
Primary endpoint: Major Adverse Events (MAE) at 30 days following surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment success at 12 months following surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upstream dilation of the main pancreatic duct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Vascular pattern (iso or hypervascular)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Lesion borders (smooth or irregular)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asprosin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: CGM Measured Time <70 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects With Serum Bactericidal Assay (hSBA) Titers ≥ the Cut-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Identification of new gene mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pulmonary nodule excision success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time Average Mean of the Maximum (TAMM) in cm/Sec
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of motor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of disability scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Distance between motor representation area localization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients achieving hematologic and molecular complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Duration of hematologic CR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Durations of hematologic and molecular CR after hematopoietic stem cell transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Preference for Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Asthma diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Active asthma symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ataxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: rate of euploidy in blastocyst
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Common side effects of IFNa therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Glucose average in 24-hour blood glucose profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to a 50% drop in baseline plasma-creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Epinephrine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serial change of ventriculo-ventricular conduction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Failure of Drug to Control Systolic Blood Pressure (SBP) < 140 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pre-sleep arousal scale (PSAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prolonged virological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in rTNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of underlying lung disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in average pain during daily activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes